Low Molecular Weight HSA Fraction Modulating Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases and T-cell mediated disorders are inadequate, with a need for improved methods to regulate the immune system and manage inflammation effectively.
Innovation Solution
Administration of a low molecular weight fraction (LMWF) of human serum albumin (HSA) containing aspartic acid-alanine-diketopiperazine (DA-DKP), which increases cyclooxygenase-2 (COX-2) levels, without concurrent administration of COX-2 antagonists, to modulate immune responses and treat T-cell mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for autoimmune diseases are used, then current standard therapies are applied, but they are inadequate and fail to effectively regulate the immune system
Solution Approach 1:
The patent changes the molecular weight parameter of human serum albumin by isolating the low molecular weight fraction (LMWF-HSA), which contains diketopiperazine structures. This parameter change transforms the therapeutic properties of albumin, enabling it to effectively regulate T-cell mediated diseases and autoimmune conditions where conventional treatments fail.
2Object-affected harmful factors
If inflammation is not controlled, then immune response proceeds unchecked, but uncontrolled immune response causes damage to the organism's own tissue
Solution Approach 1:
The low molecular weight fraction of human serum albumin acts as an intermediary substance that modulates the immune response. It interacts with T-cells and immune signaling pathways to control inflammation while preventing excessive tissue damage, thereby mediating between the immune system's defensive function and tissue protection.
3Reliability
If T-cell response is not activated, then immune protection is insufficient, but over-active T-cell response results in autoimmune diseases
Solution Approach 1:
The LMWF-HSA treatment establishes a feedback mechanism in the immune system by modulating T-cell activity. It provides immunosuppressive effects that counterbalance over-active T-cell responses, creating a regulatory feedback loop that prevents autoimmune diseases while maintaining adequate immune protection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LMWF of HSA effectively inhibits inflammation and treats T-cell mediated diseases by enhancing COX-2 activity, reducing interleukin-8 levels, and promoting anti-inflammatory pathways, thereby addressing the limitations of existing treatments.
Implementation Method 1
Administration of a low molecular weight fraction (LMWF) of human serum albumin (HSA) containing aspartic acid-alanine-diketopiperazine (DA-DKP), which increases cyclooxygenase-2 (COX-2) levels
Data Source
AI summary
The present invention provides a method of modulating various aspects of the immune system. In particular, the present invention teaches the use of diketopiperazines (DKPs) to modulate various aspects of the immune system such as, for example, inflammation, T-cells and various cytokines.